ArticleNature communications2026
CycloPepper: a machine learning platform for predicting cyclization outcomes and optimizing synthesis of therapeutic cyclopeptides.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cyclic peptides exhibit remarkable stability, membrane permeability, and binding affinity, positioning them as promising therapeutics. However, their synthesis, particularly on-resin head-to-tail cyclization, remains challenging, with cyclization site selection critically influencing yield. Here, we introduce a machine learning (ML) approach to predict cyclization outcomes, leveraging CycloBot, our fully automated cyclic peptide synthesis platform. Using this system, we generate a standardized dataset of 306 cyclic peptides (2-14 residues) and develop an ML model achieving an average prediction accuracy of 84%. Experimental validation with 74 random and therapeutic peptides showed an 86% prediction consistency. To facilitate practical use, we built CycloPepper, a user-friendly platform available through both web and software interfaces, enabling rapid cyclization site assessment. This tool effectively identified potential cyclization sites for disease-targeting peptides, including cancer biomarkers. Our work illustrates the potential of ML-assisted synthesis to streamline cyclic peptide synthesis and accelerate therapeutic discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.